Low Doses of G-CSF Prevent Cerebral Infarction and Maintain Muscle Strength in an Experimental Model of Global Ischemic Stroke

Peruch, Brunelli da Rós; Monteiro, Brenna Lepaus; Aires, Rafaela; Silva, Cristina M E; Guimarães, Marco César Cunegundes; Vasquez, Elisardo C.; Nogueira, Breno Valentim

doi:10.2174/1389201019666180718094334

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research has demonstrated the neuroprotective impact of G-CSF treatment, which is due to its high antioxidant, anti-inflammatory, and antiapoptotic properties [10,11]. In a number of ischemic rodent models, G-CSF has been demonstrated to provide long-term neuroprotection by encouraging somatic growth and improving sensorimotor and neurocognitive skills [70,71]. The neuro-regenerative and neuroprotective properties of G-CSF have also been demonstrated in preclinical studies in a number of neurodevelopmental disorders, including autism, spinal cord injury, cerebral ischemia, PD, and AD [5,10,[72][73][74].…”

Section: Neuroprotective Properties Of Granulocyte Colony-stimulating...mentioning

confidence: 99%

Neuroprotective Properties of Peptides

Erbaş¹,

Altuntaş²,

Nesil³

et al. 2023

Rare Neurodegenerative Disorders - New Insights [Working Title]

View full text Add to dashboard Cite

The development of a treatment strategy for neurodegenerative disorders is a serious issue for the healthcare world and a crucial subject of discussion. In the past two decades, a lot of focus has been placed on identifying the pathophysiological processes involved in neuronal death linked to neurodegenerative disorders and developing a variety of treatment options for neuroprotection. Numerous research teams have studied the use of peptides as neuroprotective treatments for different types of neurodegenerative disorders for a long time. The review aims to provide details about the roles of erythropoietin (EPO), glucagon-like peptide-1 (GLP-1), granulocyte colony-stimulating factor (G-CSF), and oxytocin (OXT) in neurodegenerative disorders as well as what cellular and molecular mechanisms they trigger to elicit the neuroprotective action, with a focus on neurodegenerative disorders.

show abstract